Resources

Professor Cathy Tralau-Stewart, Executive Director of the Milner Therapeutics Institute, has continued her thought leadership work with an article in Drug Discovery World.

Scancell Holdings plc, the developer of active immunotherapies to treat cancer, announces the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a registrational Phase 3 trial of its iSCIB1+ Immunobody® in advanced melanoma, with progression free survival as the agreed surrogate endpoint.

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search assignment for TreeFrog Therapeutics and is pleased to announce the placement of Mark Rothera as Chief Executive Officer (CEO).

Stablepharma will apply its proprietary stabilisation technology, initially focused on vaccines, to non-vaccine sterile injectables that currently require cold-chain storage. Stablepharma will be eligible to receive future milestone and royalty revenue from AFT upon commercialisation.

The Cell and Gene Therapy Catapult (CGT Catapult) has published new insights into the UK’s CGT clinical trials in its 2025 Advanced Therapy Medicinal Product (ATMP) Clinical Trials Database.

Infinitopes announced its second close of its seed financing round, securing an additional $15.4 million and bringing the total raised to $35.1 million.

NCIMB, the Aberdeen-based microbiology company is delighted to welcome Martin Gouldstone as chairman of the board. Martin brings a wealth of commercial and leadership expertise from drug discovery and contract research.

ELRIG announced the keynote speakers for Cell and Gene Therapy 2026 - Drs Stephen Ward (Cell and Gene Therapy Catapult) and Annarita Miccio (Imagine Institute).

The British Business Bank has made a £50 million cornerstone commitment to Epidarex Capital’s next fund.

Brainomix has been selected by Boehringer Ingelheim, the leading biopharmaceutical company providing therapeutic options for interstitial lung disease (ILD).

Coulter Partners successfully completed a search assignment for mOm Incubators and to place Daniel Green as Chief Operating Officer.

PIR International recently partnered with Slingshot Therapeutics in appointing Bobby Soni as Chief Business Officer.

AAVantgarde Bio, a clinical-stage biotechnology company pioneering therapies for inherited retinal diseases (IRDs), has announced the completion of enrollment in LUCE-1.

An acknowledgment from Astrea Bioseparations celebrating LIB Therapeutics' achievement of FDA approval for LEROCHOL™, including some collaboration efforts.

Coulter Partners successfully led a search assignment for Trevi Therapeutics, placing David Hastings as Chief Financial Officer (CFO).

OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced the closure of its £2.5 million seed funding round.

Amici Procurement Solutions Rebrands as MyAmici. The rebrand reflects the organization’s strategic evolution from a procurement-focused provider to a comprehensive, end-to-end LabOps platform supporting biotech, medtech, and life-science organisations across every stage of growth.

Complement Therapeutics is one of the leading new gene therapy companies entering into clinical trials. Based on research from the University of Manchester, the company's lead candidate CTx001 is a novel adeno-associated virus (AAV)-based gene therapy targeting an advanced form of dry AMD that leads to irreversible vision loss, with limited therapeutic options. With strong funding and an experienced management team, Complement has made rapid progress and this Fast Track designation comes after IND clearance in December.

Pioneer Group, a specialist in life science infrastructure and venture building, and global biopharmaceutical company AbbVie, have crowned Alceus Bio the winner of their 2025 Golden Ticket programme.

NRG Therapeutics Ltd has announced that the first participants have been dosed in its first-in-human Phase 1 clinical trial of its lead candidate NRG5051 being developed as a treatment for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) and Parkinson’s.